A Mab A Case Study In Bioprocess Development -

A-Mab Case Study a landmark industry document that demonstrates how Quality by Design (QbD)

principles can be applied to develop a monoclonal antibody (mAb)

. Created by the CMC Biotech Working Group, it serves as a roadmap for systematically evaluating product quality, safety, and efficacy through process understanding. International Society for Pharmaceutical Engineering (ISPE) 1. Foundations: Defining the Product

The process begins by establishing the "end goal" before any manufacturing starts. International Society for Pharmaceutical Engineering (ISPE) Target Product Profile (TPP):

Defines the clinical goals, including safety, efficacy, and dosage. Critical Quality Attributes (CQAs):

Identifies physical, chemical, or biological properties (e.g., glycosylation, purity, bioactivity) that must be controlled to ensure product quality. Initial Risk Assessment: Uses tools like Failure Mode and Effects Analysis (FMEA) to rank which process parameters might impact CQAs. International Society for Pharmaceutical Engineering (ISPE) 2. Upstream Process Development A Mab A Case Study In Bioprocess Development

This stage focuses on producing the antibody within a biological system. uml.edu.ni Cell Line Development: Engineering and selecting stable host cells (typically ) with high productivity. Media & Feed Strategy:

Developing optimal nutrient "recipes" and feeding schedules to maximize cell growth and antibody titers. Bioreactor Optimization: Controlling parameters like dissolved oxygen (DO) , pH, and temperature. The A-Mab study emphasizes using Design of Experiments (DoE)

to find the "Design Space"—the range where these factors can vary without affecting the product. PharmTech.com 3. Downstream Process Development (Purification)

Once the mAb is produced, it must be isolated and purified from the cell culture. Contentstack A–Mab: A Case Study in Bioprocess Development - ISPE 30 Oct 2009 —

Even after Protein A, impurities remain. We implemented a two-step polishing phase: A-Mab Case Study a landmark industry document that

This "flow-through" polishing step ensured that mAb-X achieved a purity level of >99.5%.

Molecule: Humanized IgG1 mAb targeting a cancer antigen. Indication: Solid tumors. Target Dose: 500 mg per patient, every 3 weeks. Annual Demand: 50 kg (clinical → early commercial). Critical Quality Attributes (CQAs):

For subcutaneous delivery, the final drug product must be <2 mL volume. Mab-X is formulated at 150 mg/mL. Stability studies (4 weeks at 40°C) show that adding 0.02% polysorbate-80 prevents agitation-induced aggregation, but excess PS-80 causes visible particles. The optimized formulation is: 150 mg/mL Mab-X, 10 mM histidine, 150 mM arginine, 5% trehalose, 0.02% PS-80, pH 6.0.

Using tangential flow filtration (TFF) with 30 kDa cassettes, the team concentrates Mab-X from 2 mg/mL to 120 mg/mL. Viscosity becomes the enemy. At 100 mg/mL, viscosity reaches 25 cP, causing high pump shear and membrane fouling.

Innovation: The team adjusts the buffer to 10 mM histidine (pH 6.0) with 150 mM arginine and 5% trehalose. This combination reduces viscosity to 8 cP at 120 mg/mL, allowing efficient TFF. Even after Protein A, impurities remain

| Metric | Standard Process (Benchmark) | Optimized Process (Case Study) | | :--- | :--- | :--- | | Overall Yield | 55% | 71% | | Cost of Goods (COG/g) | $150 | $78 | | Time to Tox (DNA to in vivo) | 11 months | 9 months | | Facility Footprint | 3 Skids (Capture, polish, virus) | 2 Skids (Intensified capture + polish) |

From this case study on Mab-X, the bioprocess development community can extract four universal lessons:

Initial serum-free media yielded only 1.5 g/L of A Mab. The bioprocess team performed a Design of Experiments (DoE) screening 24 components. The breakthrough came with:

Final Fed-Batch Process: